Find information on submassive pulmonary embolism diagnosis, including clinical documentation requirements, medical coding (ICD-10 I26), symptoms, risk factors, and treatment. Learn about the difference between massive and submassive PE, diagnostic testing like CTPA and VQ scan, and appropriate healthcare management for optimal patient outcomes. This resource provides guidance for physicians, nurses, and other healthcare professionals involved in the care of patients with submassive pulmonary embolism.
Also known as
Pulmonary embolism with acute cor pulmonale
Submassive PE causing right heart strain.
Other pulmonary embolism
Unspecified PE, may include submassive.
Pulmonary embolism, unspecified
General PE code, can be used if subtype unknown.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is there right heart strain or RV dysfunction?
When to use each related code
| Description |
|---|
| Submassive PE |
| Massive PE |
| Low-risk PE |
Coding submassive PE requires documented right heart strain or elevated biomarkers, differentiating it from massive or non-massive PE. Lack of specific documentation poses a risk.
Saddle PE, while often submassive, needs distinct documentation. Coding it solely as submassive without specifying saddle morphology can lead to underreporting severity.
Submassive PE is acute. Chronic PE, even with similar symptoms, has different codes. Misinterpreting chronicity can lead to inaccurate coding and potential overpayments.
Q: How does right ventricular dysfunction in submassive pulmonary embolism impact prognosis and guide treatment decisions?
A: Right ventricular dysfunction (RVD) is a crucial prognostic indicator in submassive pulmonary embolism (PE). While hemodynamically stable, patients with RVD and evidence of myocardial injury (e.g., elevated troponin) have a higher risk of adverse outcomes, including hemodynamic decompensation and death. Echocardiography plays a vital role in assessing RVD by demonstrating right ventricle enlargement, hypokinesis, or elevated pulmonary artery pressure. The presence of RVD, alongside myocardial injury biomarkers, guides the escalation of treatment from anticoagulation alone to considering advanced therapies such as systemic thrombolysis or catheter-directed thrombolysis. Explore how risk stratification strategies incorporating RVD and biomarkers can inform personalized treatment approaches for submassive PE. Consider implementing a standardized echocardiography protocol for all suspected submassive PE patients to aid in early risk stratification.
Q: What are the best practices for differentiating submassive pulmonary embolism from massive pulmonary embolism in the ED setting?
A: Differentiating submassive PE from massive PE requires a rapid assessment of hemodynamic stability and evidence of right ventricular dysfunction. Massive PE presents with hypotension (systolic blood pressure < 90 mmHg or a drop of 40 mmHg for >15 minutes) or signs of shock, requiring immediate intervention. Submassive PE, while not hypotensive, often presents with signs of right heart strain like tachycardia, tachypnea, and elevated jugular venous pressure. Alongside clinical assessment, point-of-care ultrasound, ECG, and biomarkers (BNP, troponin) help differentiate. In the ED, rapid triage and risk stratification are essential, with massive PE needing immediate thrombolysis or embolectomy. Learn more about incorporating bedside ultrasound and biomarkers into your PE diagnostic algorithm to quickly identify high-risk patients. Consider implementing a standardized rapid response protocol for suspected massive PE.
Submassive pulmonary embolism diagnosed. Patient presents with acute onset dyspnea and pleuritic chest pain. Symptoms began two days prior to presentation and progressively worsened. Risk factors for pulmonary embolism elicited, including recent prolonged immobility following a lower extremity surgery two weeks prior. Physical exam reveals tachycardia, tachypnea, and mild hypoxemia on room air. ECG demonstrates sinus tachycardia with nonspecific T-wave abnormalities. D-dimer level significantly elevated. Computed tomography angiography of the chest confirms the presence of pulmonary emboli within the segmental and subsegmental pulmonary arteries, consistent with a submassive PE. Right heart strain is evident on the CTA, indicated by right ventricular enlargement and interventricular septal bowing towards the left ventricle. Patient exhibits no signs of hemodynamic instability. Troponin levels are mildly elevated, indicating right heart stress. Assessment includes acute pulmonary embolism, submassive, with right heart strain. Plan includes initiation of anticoagulation therapy with [Specify anticoagulant, e.g., apixaban, rivaroxaban, low molecular weight heparin] for treatment of PE and prevention of recurrent thromboembolic events. Patient education provided regarding the diagnosis, treatment plan, medication administration, potential side effects, and follow-up care. Referral to Thrombosis Clinic for long-term anticoagulation management. Patient will be monitored for bleeding complications, recurrent PE, and resolution of symptoms. Prognosis guarded but currently stable. Discharge pending resolution of symptoms and adequate therapeutic anticoagulation levels. Follow-up scheduled in one week for reassessment and ongoing management.